抗肿瘤药物脂质体的研究进展  

Progress in liposomes as anti-tumor agent

作　　者：张晓燕[1] 高永良[1] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国新药与临床杂志》2009年第5期333-336,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：多数抗肿瘤药物对肿瘤细胞的杀伤作用并没有选择性,同时也作用于正常细胞,从而带来了较多的不良反应,很大程度上影响了病人的治疗效果和生活质量。脂质体这一新型药物传递系统的出现,使抗肿瘤药物高效低毒治疗恶性肿瘤成为可能。脂质体已成为抗肿瘤药物研发的一大热点。本文对已经上市和处于临床试验阶段的一些抗肿瘤药物脂质体的研究进展进行综述。Most common cells. This lack of patients. Liposome, a of the antineoplastic agents are not specific for cancer cells and are also cytotoxic to of specificity results in a significant influence on the therapeutic effects and life quality novel drug delivery system, is a great progress in cancer therapy for high efficiency and low toxicity. The research and development of anti-tumor agent liposome have been a hot topic in recent years. This review mainly focuses on the research progress in liposomal anti-tumor agents, which are available in clinical trials or on the market.

关 键 词：脂质体 抗肿瘤药 综述 

分 类 号：R961[医药卫生—药理学]